Trial Profile
The Efficacy and Safety of Bimatoprost SR in Patients With Open-angle Glaucoma or Ocular Hypertension
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 16 Feb 2023
Price :
$35
*
At a glance
- Drugs Bimatoprost (Primary) ; Timolol
- Indications Ocular hypertension; Open-angle glaucoma
- Focus Registrational; Therapeutic Use
- Acronyms ARTEMIS; ARTEMIS 2
- Sponsors AbbVie; Allergan
- 01 Jan 2023 Results from NCT02247804 and NCT02250651; evaluating the time course of biodegradation of an intracameral, biodegradable, sustained-release bimatoprost implant that lowers intraocular pressure without the need for daily eye drops, published in the Journal of Ocular Pharmacology and Therapeutics
- 28 May 2022 Results of a pooled analysis of data from 2 phase III studies and one phase I/II study (NCT02247804, NCT02250651, and NCT01157364) assessed the single administration of intracameral Bimatoprost implant 10 µg in patients with Open-Angle Glaucoma or Ocular Hypertension, published in the Ophthalmology and Therapy
- 01 Nov 2021 Primary endpoint has been met. (Change From Baseline in Intraocular Pressure (IOP) in the Study Eye to Week 12 (Hours 0 and 2) for 15 g), as per Results published in the Drugs